Solthis Solidarité Thérapeutique et Initiatives pour la Santé

Do not wait for the crisis to act

Donate now

Call for access to hepatitis C diagnostics, treatment and care for all

Juillet 2012

27 July 2012 |  Position statement |  ,

ADVOCACYHEALTH FINANCINGHEALTH PRODUCTS AND PHARMACEUTICAL SYSTEMHEPATITIS

Over the last decade, HIV drug prices have dropped dramatically, and access to antiretroviral therapy has significantly increased. It is time to apply the lessons from HIV/AIDS to hepatitis C virus (HCV). An estimated 170 million people have chronic hepatitis C. At least 350,000 of them die from it each year although it is curable. Access to prevention tools, diagnostics, and treatment remains extremely limited, particularly for people who inject drugs, a group disproportionately affected by HCV. Few people in the Global South have access, even those living with HIV/AIDS.

Therefore, on the occasion of the XIX International Aids Conference in Washington, DC, USA, and the eve of World Hepatitis Day, the undersigned grassroots civil society groups and non-governmental organizations have formed an international coalition working towards universal access to HCV voluntary testing and treatment.
We call upon :

  • The pharmaceutical companies – particularly Roche & Merck – to drastically reduce the price of diagnostics and treatment regimens for the estimated 170 million individuals suffering from chronic hepatitis C, particularly those with HIV co-infection.
  • Political leaders to mobilize the adequate resources needed now and in the future—in anticipation of new HCV drugs— to diagnose, monitor and treat high-prevalence populations, such as people living with HIV/AIDS and people who inject drugs
  • The World Health Organization (WHO) and other relevant United Nations (UN) agencies to develop treatment guidelines for HCV treatment for HIV/HCV co-infected people and HCV mono-infected persons in low and middle income countries and to develop a prequalification process for bio-similars that facilitates access to pegylated interferon
  • Researchers to gather and provide evidence on feasibility and effectiveness of treatment in low and middle income countries, with a focus on disproportionately affected populations, particularly people who inject drugs. International donors to support community mobilization and treatment preparedness and literacy, as well as treatment cost, which are crucial for access to treatment.

Twitter

Facebook

Events

No event has been found

Fri

19

Nov

From 19 November 2021 to 21 November 2021

AFRAMED 2021

AFRAMED 2021

Hammamet, Tunisie

HEPATITISHIV / AIDS


Mon

06

Dec

From 6 December 2021 to 11 December 2021

Solthis at ICASA 2021

Solthis at ICASA 2021

HIV / AIDS

Tout afficher

© Solthis 2021 - All rights reserved | Legal notice | Personal data | Cookie Management | Sitemap